
Company valuation, historical trends, and peer comparisons.
According to Prime Medicine, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 966.47M. This represents a change of 33.71% compared to the average of 722.80M of the last 4 quarters.
The mean historical Enterprise Value of Prime Medicine, Inc. over the last ten years is 1.06B. The current 966.47M Enterprise Value has changed -8.49% with respect to the historical average. Over the past ten years (40 quarters), PRME's Enterprise Value was at its highest in in the December 2022 quarter at 1.65B. The Enterprise Value was at its lowest in in the December 2019 quarter at 0.
Average
1.06B
Median
1.30B
Minimum
204.63M
Maximum
1.65B
Discovering the peaks and valleys of Prime Medicine, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 178.35%
Maximum Annual Enterprise Value = 1.65B
Minimum Annual Increase = -73.70%
Minimum Annual Enterprise Value = 204.63M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 569.59M | 178.35% |
| 2024 | 204.63M | -73.70% |
| 2023 | 778.05M | -52.77% |
| 2022 | 1.65B | 27.07% |
| 2021 | 1.30B | -9.62% |
| 2020 | 1.43B | -1.94% |
The current Enterprise Value of Prime Medicine, Inc. (PRME) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
517.42M
5-year avg
899.18M
10-year avg
1.06B
Prime Medicine, Inc.’s Enterprise Value is greater than Editas Medicine, Inc. (251.43M), less than Scribe Therapeutics Inc. (0), greater than Metagenomi, Inc. Common Stock (28.54M), less than Intellia Therapeutics, Inc. (1.69B), less than Beam Therapeutics Inc. (2.90B), less than CRISPR Therapeutics AG (5.59B), greater than Caribou Biosciences, Inc. (48.10M), greater than Design Therapeutics, Inc. (651.85M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 251.43M | $417.74M | |
| 0 | $271.53M | |
| 28.54M | $29.84M | |
| 1.69B | $1.72B | |
| 2.90B | $2.87B | |
| 5.59B | $5.01B | |
| 48.10M | $47.64M | |
| 651.85M | $665.24M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prime Medicine, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Prime Medicine, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Prime Medicine, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Prime Medicine, Inc. (PRME)?
What is the 3-year average Enterprise Value for Prime Medicine, Inc. (PRME)?
What is the 5-year average Enterprise Value for Prime Medicine, Inc. (PRME)?
How does the current Enterprise Value for Prime Medicine, Inc. (PRME) compare to its historical average?